India's $1B nutraceutical market hits trust test as HUL-OZiva deal signals consolidation
Direct-to-consumer nutraceutical category at $1B faces credibility crisis from influencer misinformation and weak scientific validation, even as FSSAI formalises rules. HUL's ₹824 cr OZiva buyout for 49% stake marks institutional consolidation. Sector growing 10.5-13% YoY in FY26, with $23-85B potential by 2034 against under-2 products per person vs Japan's 350.
What happened
Indian Nutraceutical Industry · India's $1B nutraceutical market faces credibility test from influencer misinformation and weak scientific validation. FSSAI
Key facts
- $1 billion direct consumer market
- $8.9B-$38.7B manufacturing ecosystem
- 10.5%-13% YoY FY26 growth
- ₹824 crore HUL-OZiva deal for 49% stake
- $23B-$85B by 2033-34
- India <2 vs Japan ~350 products per person
Why this matters
HUL's ₹824 cr OZiva move resets the clearing price for D2C nutraceutical assets, so move on credible mid-tier targets before strategics and FSSAI formalisation compress the buyable universe.